Advisors Asset Management Inc. decreased its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 35.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,299 shares of the company’s stock after selling 71,760 shares during the quarter. Advisors Asset Management Inc.’s holdings in Eli Lilly and were worth $11,231,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and in the second quarter valued at $128,000. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and in the second quarter valued at $129,000. Point72 Asia Hong Kong Ltd boosted its holdings in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new position in Eli Lilly and in the second quarter valued at $148,000. Institutional investors and hedge funds own 76.31% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock worth $22,041,236 in the last three months. Corporate insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) traded up $0.59 on Friday, reaching $86.98. The company’s stock had a trading volume of 2,728,900 shares, compared to its average volume of 3,260,000. Eli Lilly and Co has a 12 month low of $74.00 and a 12 month high of $89.09. The stock has a market cap of $95,770.00, a price-to-earnings ratio of 41.42, a PEG ratio of 1.62 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.59%. Eli Lilly and’s payout ratio is 99.05%.
A number of research firms recently issued reports on LLY. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen reaffirmed a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and an average price target of $92.14.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/01/13/advisors-asset-management-inc-has-11-23-million-holdings-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.